CORONARY INTERVENTIONS

Polymer-free drug-coated coronary stents are cost-effective in patients at high bleeding risk: economic evaluation of the LEADERS FREE trial

EuroIntervention 2018;13:1688-1695 published online September 2017. DOI: 10.4244/EIJ-D-17-00286

Antoine Filipovic-Pierucci1*, MD, MPH; Isabelle Durand-Zaleski1,2,3, MD, PhD; Thibault Butel1, MD, MPH; Samantha Greene4, BA; Thomas Hovasse5, MD; Andres Iñiguez6, MD, PhD, FESC; Marco Stefano Nazzaro7, MD, PhD; Keith G. Oldroyd8, MBChB, MD; Suneel Talwar9, MBBS, MRCP, MD; Gert Richardt10, MD; Ute Windhovel11, PhD; Philip Urban12, MD; Marie-Claude Morice5, MD; for the LEADERS FREE investigators

1. Assistance Publique Hopitaux de Paris, URC Eco & Santé Publique, Hôpital Henri Mondor, Créteil, France; 2. Université Paris Est Créteil, Créteil, France; 3. INSERM ECEVE UMR 1123, Paris, France; 4. Biosensors, Morges, Switzerland; 5. Hôpital Privé

Aims: In patients at high risk of bleeding who undergo PCI, the Biolimus A9 polymer-free drug-coated stent (DCS) has superior efficacy and safety compared to a bare metal stent (BMS). We

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bare metal stentclinical trialscost-effectivenessclinical researchquality of lifestent thrombosis

Share on Facebook Share on Twitter Share on Linkedin